Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a ...

Short-term memory loss can be a sign of early-stage Alzheimer's disease. It can manifest as difficulty creating new memories or problems retrieving them. For example, someone with early Alzheimer's ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving biomarkers. The trials were global, involved ...

Scientists from Northwestern University and elsewhere have published details of a study that links short strands of toxic RNAs to brain cell death and DNA damage in Alzheimer’s disease and aged brains ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

In a recent study published in Nature Communications, a group of researchers explored how Death Induced by Survival gene Elimination (DISE) through the analysis of ribonucleic acid (RNA)-induced ...

As people age, cognitive dysfunction known as dementia becomes more likely. Alzheimer's disease is the most common cause of dementia. Scientists are still working to determine the cause of Alzheimer's ...

Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in ...

Alzheimer's disease, which is expected to have affected about 6.7 million patients in the U.S. in 2023, results in a substantial loss of brain cells. But the events that cause neuron death are poorly ...

Short telomeres might lead to increased risk of Alzheimer’s disease, but observational analyses have been inconclusive and potentially confounded by the strong association of both telomere length and ...

Some call them soluble oligomers, others prefer the term protofibrils. Regardless, most researchers agree on two things when it comes to free-wheeling aggregates of Aβ: They are more toxic than their ...

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease. And in a recent small study, the antidepressant effects of ketamine lasted longer ...